Capricor Therapeutics, Inc. (CAPR)
$3.61
Rating:
Recommendation:
Neutral
| Symbol | CAPR |
|---|---|
| Price | $3.61 |
| Beta | 5.391 |
| Volume Avg. | 0.11M |
| Market Cap | 87.810M |
| Shares () | - |
| 52 Week Range | 2.56-5.85 |
| 1y Target Est | - |
| DCF Unlevered | CAPR DCF -> | |
|---|---|---|
| DCF Levered | CAPR LDCF -> | |
| ROE | -8.52% | Neutral |
| ROA | -4.14% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 163.45% | Buy |
| P/E | - | |
| P/B | 3.56 | Strong Buy |
Latest CAPR news
About
Download (Excel)Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.